SBIR/STTR Research Award

Novel Drug Discovery Tools for Depression and Anxiety

Award identifier bd39d6d19a5aa87a35ffa131245ffb60047671736a79eca28b3839fa4f9882dfAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$131,414

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PROMOTER NEUROSCIENCES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Stress is a significant factor that can precipitate, exacerbate, and maintain psychopathology. The corticotropin-releasing factor (CRF) system has been implicated in mediating the stress response and linking it to psychopathology. Over-activity of the CRF system is implicated in depression, anxiety, and perhaps other stress-related disorders such as irritable bowel syndrome. Abundant preclinical evidence indicates that treatments targeting this system offer a promising approach for treating certain neuropsychiatric, as well as, other stress-related physical illnesses. Promoter Neuroscience (PNS) has developed intellectual property related to the promoter sequences of the CRF family of genes and is developing screening tools for drug discovery. PNS has demonstrated the feasibility of using cell cultures transiently transfected with CRF system promoter reporter constructs as high throughput screening tools. The proposed studies will further develop PNS's proprietary technologies and help accelerate the discovery of compounds capable of altering expression of the CRF system. To improve this technology and to make a drug-screening tool relevant to humans, we will transfer our technology to human cortical neuronal cultures, which are derived from a brain region that naturally expresses CRF receptors and has been implicated in mediating the psychopathology. One set of cells will be transfected with constructs containing the human CRF receptor 2a (CRF2a) promoter driving expression of the Lucifer's reporter gene. Separate cortical neuronal cultures will be stably transfected with constructs containing the luciferase reporter gene under control of the human CRF receptor 1 (CRF1) promoter. Studies will characterize the basal levels of expression from the stably transfected cultures. To begin to explore potential new therapeutic approaches, expression from the stably transfected cultures will be monitored following treatment with compounds known to activate several different intracellular pathways. Activation of these intracellular pathways will lead to stimulation of transcription factors that bind to putative cis-regulatory elements identified within the CRF1 and CRF2a promoter regions. The stably transfected human cortical neuronal cultures will provide models relevant to human brain function that will provide PNS with the potential to discover new drugs that regulate CRF receptor expression.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.